dpp 4 glp 1 combination DPP-4 INHIBITORS - Dipeptidyl Peptidase-4 Inhibitor - Gliptins GLP-1-RA and DPP-4 inhibitors in

The drug carries significant safety information, including potential thyroid tumors and pancreatitis risks, among others

Obesity and overweight, which are common in patients with DM2, are a factors that favor the development/progression of CKD through both direct and indirect effects.69 Although the precise mechanisms the association between obesity and CKD are not totally defined it has been proposed that hypertension, glomerular hyperfiltration, hyperglycemia, lipid toxicity, inflammation or the role of adipose tissue and its adipokines are involved.70 Weight reduction by bariatric surgery, pharmacological treatment or dietary measures are associated with a nephroprotective effect,7173 so that weight reduction is a fundamental objective in the nephroprotection of patients with DKD

Treatments such as Astras Qternmet XR and Lilly-BIs Trijardy XR have shown significant improvement in glycemic control and are generally well tolerated by patients

Currently, 40% of Americans are obese and another 30% are overweight

This peptide therapy may be incorporated into personalized wellness programs under provider supervision